| Literature DB >> 33590897 |
Tiangui Yang1, Xi Fu1, Peng Fu1, Jie Chen1, Changlu Xu1, Xiaoxia Liu1, Tiesheng Niu1.
Abstract
BACKGROUND: Fragmented QRS (fQRS) is a marker of local myocardial scar. This study aimed to analyze the relationship between fQRS and coronary collateral circulation (CCC) and evaluate the predictive value of fQRS for long-term clinical outcomes among patients with chronic total occlusion (CTO) and prior myocardial infarction (MI) who underwent percutaneous coronary intervention (PCI).Entities:
Keywords: chronic total occlusion; fragmented QRS; major adverse cardiovascular events; percutaneous coronary intervention
Year: 2021 PMID: 33590897 PMCID: PMC8027581 DOI: 10.1002/clc.23573
Source DB: PubMed Journal: Clin Cardiol ISSN: 0160-9289 Impact factor: 2.882
Comparison of general baseline data among three groups (−x ± s; median [IQR]; n, %)
| Characteristic | Group A (no Q wave and fQRS, | Group B (fQRS, | Group C (Q wave, |
|
|---|---|---|---|---|
| Basic data | ||||
| Age > 65 Y ( | 58 (28.2%) | 81 (30.6%) | 104 (26.6%) | .082 |
| Male ( | 102 (49.5%) | 131 (49.4%) | 226 (57.8%) | .003 |
| The course of MI (years) | 6.4 (1.0) | 6.5 (1.1) | 6.4 (1.2) | .089 |
| Smoking ( | 112 (54.4%) | 154 (58.1%) | 185 (47.3%) | .002 |
| Hypertension ( | 98 (47.6%) | 132 (49.8%) | 180 (46.0%) | .374 |
| The course of hypertension (years) | 6.2 (1.0) | 6.3 (1.1) | 6.3 (1.2) | .495 |
| Diabetes ( | 71 (34.5%) | 109 (41.1%) | 137 (35.0%) | .049 |
| Course of diabetes (years) | 6.8 (1.2) | 6.9 (1.3) | 6.7 (1.3) | .078 |
| Cerebrovascular disease ( | 11 (5.3%) | 18 (6.9%) | 38 (9.7%) | .094 |
| BMI (kg / m2) | 25.4 ± 4.7 | 25.9 ± 4.8 | 25.7 ± 5.1 | .277 |
| Family history of MI ( | 9 (4.4%) | 18 (6.8%) | 37 (9.5%) | .043 |
| Medication ( | ||||
| Aspirin | 206 (100%) | 265 (100%) | 391 (100%) | 1 |
| Clopidogrel | 113 (54.9%) | 150 (56.6%) | 214 (54.7%) | .552 |
| Ticagrelor | 93 (45.1%) | 115 (43.4%) | 177 (42.3%) | .578 |
| Statins | 206 (100%) | 265 (100%) | 391 (100%) | 1 |
| Beta‐blocker | 142 (68.9%) | 196 (73.9%) | 290 (74.2%) | .537 |
| ACEIs/ARBs | 129 (62.6%) | 162 (61.1%) | 260 (66.5%) | .324 |
| Biochemical index | ||||
| CHOL (mmol/L) | 4.7 ± 3.1 | 4.7 ± 2.9 | 4.9 ± 2.8 | .342 |
| TGs (mmol/L) | 3.0 (0.9) | 3.2 (1.0) | 3.0 (1.1) | .515 |
| LDL (mmol/L) | 3.4 ± 1.7 | 3.3 ± 1.8 | 3.5 ± 1.8 | .501 |
| HbA1c (%) | 7.3 ± 3.7 | 7.4 ± 3.5 | 7.2 ± 3.8 | .281 |
| FPG (mmol/L) | 7.5 ± 4.7 | 7.6 ± 4.2 | 7.5 ± 4.5 | .312 |
| Cr (umol / L) | 81.1 ± 22.9 | 84.1 ± 23.3 | 76.4 ± 25.1 | .055 |
| Distribution of CTO lesions ( | <.001 | |||
| LAD | 64 (31.1%) | 97 (36.6%) | 123 (31.5%) | — |
| LCX | 62 (30.1%) | 42 (15.9%) | 120 (30.7%) | — |
| RA | 80 (38.8%) | 126 (47.5%) | 148 (37.8%) | — |
|
| <.001 | |||
| Poor | ||||
| Grade 0 CCC | — | — | — | — |
| Grade 1 CCC | 12 (5.8%) | 31 (11.7%) | 67 (17.1%) | — |
| Good | ||||
| Grade 2 CCC | 16 (7.8%) | 30 (11.3%) | 72 (18.4%) | — |
| Grade 3 CCC | 178 (86.4%) | 204 (77.0%) | 252 (64.5%) | — |
| NO. of stents per patient | 3.0 (0.4) | 3.0 (0.5) | 3.0 (0.4) | .512 |
| Mean stent diameter (mm) | 3.4 (0.9) | 3.5 (0.9) | 3.4 (0.8) | .118 |
| Mean stent length (mm) | 52.7 ± 20.5 | 53.1 ± 21.8 | 54.1 ± 20.3 | .411 |
| Total procedure time (min) | 114.1 ± 45.3 | 116.1 ± 51.3 | 114.8 ± 55.6 | .159 |
| Site of access ( | .312 | |||
| Femoral | 174 (84.5%) | 219 (82.7%) | 316 (80.8%) | — |
| Radial | 9 (4.4%) | 12 (4.5%) | 19 (4.9%) | — |
| Femoral and radial | 23 (11.1%) | 34 (12.8%) | 56 (14.3%) | — |
| Successful technique ( | .154 | |||
| Forward wire Technique | 141 (68.4%) | 174 (65.7%) | 261 (66.7%) | — |
| Reverse wire Technique | 65 (31.6%) | 91 (34.3%) | 130 (33.3%) | — |
| IVUS used ( | 64 (31.1%) | 85 (32.1%) | 132 (33.8%) | .612 |
| PTCRA used ( | 14 (6.8%) | 17 (6.4%) | 21 (5.4%) | .218 |
Abbreviations: ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CCC, coronary collateral circulation; CHOL, total cholesterol; Cr, creatinine; CTO, chronic total occlusion; FPG, fasting plasma glucose; HbA1c, glycosylated hemoglobin A1c; IVUS, intravascular ultrasound; LAD, left anterior descending; LCX, left circumflex; LDL, low‐density lipoprotein; MI, myocardial infarction; PTCRA, percutaneous transluminal coronary rotational atherectomy; RCA, right coronary artery; TG, triglyceride.
Change of cardiac function after PCI (x ± s)
| Characteristic | Group A (no Q wave and fQRS, | Group B (fQRS, | Group C (Q wave, |
|
|
|
|
|---|---|---|---|---|---|---|---|
| Before PCI | |||||||
| 6MWT (m) | 379.6 ± 136.7 | 372.3 ± 134.9 | 367.4 ± 141.1 | .315 | .181 | .214 | .118 |
| BNP (ng/ml) | 315.3 ± 125.6 | 324.6 ± 134.6 | 345.6 ± 129.9 | .129 | .082 | .064 | .071 |
| LVEF (%) | 47.8 ± 7.9 | 47.1 ± 8.6 | 46.1 ± 9.0 | .512 | .296 | .421 | .112 |
| LVEDVI (ml/m2) | 80.1 ± 9.8 | 79.1 ± 10.2 | 81.1 ± 9.5 | .452 | .318 | .311 | .213 |
| 12‐months follow up | |||||||
| 6MWT (m) | 451.6 ± 178.1 | 452.9 ± 186.1 | 415.3 ± 174.1 | .418 | .012 | .011 | <.001 |
| BNP (ng/ml) | 211.9 ± 109.4 | 226.6 ± 115.9 | 300.1 ± 119.4 | .311 | .009 | .012 | <.001 |
| LVEF (%) | 57.9 ± 8.7 | 53.6 ± 8.9 | 52.1 ± 9.4 | .018 | .011 | .229 | .001 |
| LVEDVI (ml/m2) | 74.4 ± 10.6 | 78.1 ± 10.1 | 78.6 ± 9.5 | .021 | .017 | .312 | .002 |
| 24‐months follow up | |||||||
| 6MWT (m) | 495.3 ± 156.1 | 501.1 ± 166.9 | 462.6 ± 163.9 | .412 | .046 | .031 | <.001 |
| BNP (ng/ml) | 181.6 ± 102.7 | 189.2 ± 114.4 | 254.7 ± 127.1 | .487 | .008 | .001 | <.001 |
| LVEF (%) | 60.1 ± 8.5 | 59.1 ± 9.2 | 56.3 ± 7.9 | .399 | .016 | .021 | .002 |
| LVEDVI (ml/m2) | 70.6 ± 8.9 | 71.1 ± 9.5 | 75.1 ± 10.2 | .316 | .013 | .008 | .001 |
Abbreviations: 6MWT,6‐minute walking test; BNP, brain natriuretic peptide; LVEF, left ventricular ejection fraction; LVEDVI, left ventricular end‐diastolic volume index; PCI, percutaneous coronary intervention.
Long‐term clinical outcomes of patients in three groups up to 2 years (n, %)
| Characteristic | Group A (no Q wave and fQRS, | Group B (fQRS, | Group C (Q wave, |
|
|
|
|
|---|---|---|---|---|---|---|---|
| All MACEs ( | 14 (6.8%) | 19 (7.2%) | 44 (11.3%) | .390 | .039 | .043 | .045 |
| All‐cause death | 2 (1.0%) | 4 (1.5%) | 13 (3.3%) | .259 | .040 | .049 | .046 |
| Cardiac death | 2 (1.0%) | 3 (1.1%) | 10 (2.6%) | .454 | .050 | .054 | .052 |
| All MI | 4 (1.9%) | 6 (2.3%) | 20 (5.1%) | .124 | .026 | .041 | .031 |
| Revascularization | 9 (4.4%) | 14 (5.3%) | 34 (8.7%) | .175 | .028 | .039 | .030 |
| Definite/probable ST | 6 (2.9%) | 8 (3.0%) | 24 (6.1%) | .526 | .037 | .044 | .042 |
| MA | 1 (0.5%) | 4 (1.5%) | 12 (3.1%) | .119 | .056 | .127 | .079 |
| CHF | 2 (1.0%) | 3 (1.1%) | 10 (2.6%) | .543 | .212 | .301 | .245 |
| Ischemic stroke | 1 (0.5%) | 2 (0.8%) | 0 | .398 | .229 | .312 | .254 |
Abbreviations: CHF, congestive heart failure; MACE, major adverse cardiovascular events; MI, myocardial infarction; MA, malignant arrhythmia; ST, stent thrombosis.
FIGURE 1The Kaplan Meier curves for clinical outcomes. The cumulative incidence rate of all MACEs, all‐cause death, all MI, any revascularization, and definite/probable ST in group B was similar to that in group A; both of them were significantly lower than that in group C (All MACEs: Log‐rank P = 0.008, (A) All‐cause death: Log‐rank p = .045, (B) All MI: Log‐rank p = .028, (C) Any revascularization: Log‐rank p = .017, (D) Definite/probable ST: Log‐rank p = .021, (E) MACE: major adverse cardiovascular events; MI, myocardial infarction; ST, stent thrombosis
FIGURE 2Multivariate Cox regression analysis. When adjusted for Q wave (group C), no Q wave and fQRS (group A), good CCC, smoking, hypertension, diabetes, family history of MI, male, age > 65y, mean stent diameter, mean stent length, LVEF, and LDL, fQRS is an independent protective factor for MACE within 2 years after PCI (RR = 0.668, 95% CI [0.422–0.917], p = .001). CCC, coronary collateral circulation; LDL: low‐density lipoprotein; LVEF: left ventricular ejection fraction; MACE, major adverse cardiovascular events; MI, myocardial infarction; PCI, percutaneous coronary intervention